XGN

EXAGEN INC

XGN·30068X103·US·Common Stock·Healthcare - Diagnostics & Research-13D/G

XGN (EXAGEN INC) is held by 40 institutional investors as of Q1 2026. Largest holders: BALYASNY ASSET MANAGEMENT L.P. ($2.4M), VANGUARD CAPITAL MANAGEMENT LLC ($2M), SILVERCREST ASSET MANAGEMENT GROUP LLC ($1.6M). Net institutional sentiment: Mixed.

40
Holders
Avg rating(7 Elite)
$16.2M
Total Value
35% (53)
Fund Consensus
17 buying - 32 selling
XGNSmart Money Verdict
View all
Held by 40 funds
7 elite
Who's Trading
ActivistPUParian Ultreia LP5.3%May 27, 2026
ActivistCJChernett Jorey9.9%May 20, 2026
InsiderAJABALLI JOHNSell $57KMar 3, 2026
InsiderAJABALLI JOHNSell $41KFeb 24, 2026
InsiderBGBlack Jeffrey G.Sell $6KFeb 24, 2026
ActivistRTW Investments, LPRTW Investments, LP4.9%Feb 17, 2026
ActivistNCNMSIC Co-Investment Fund, L.P.6.0%Feb 11, 2026
InsiderAJABALLI JOHNSell $376KOct 16, 2025
InsiderBGBlack Jeffrey G.Sell $200KSep 2, 2025
ActivistLLLYTTON LAURENCE W1.0%Aug 14, 2025
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Decreased
796,632(-13.3%)$2.4M0.0%-34.64%
0
New
678,652$2M0.0%+29.74%
36
Decreased
537,870(-10.0%)$1.6M0.0%-66.86%
0
Decreased
395,231(-50.0%)$1.2M0.0%-57.31%
0
Increased
288,825(+228.1%)$866,4750.0%+5.54%
40
Increased
244,240(+107.0%)$732,7200.0%-4.84%
40
Increased
242,285(+149.8%)$726,8550.0%-5.59%
40
Increased
236,735(+22.0%)$710,2050.0%-41.46%
30
Increased
231,115(+22.6%)$693,3450.0%-43.87%
30
Increased
203,272(+47.3%)$609,8160.0%-14.12%
33
Increased
178,857(+3.6%)$536,9220.0%-60.44%
17
Decreased
157,821(-57.1%)$473,4630.0%-47.28%
0
Increased
129,710(+297.8%)$389,1300.0%+9.11%
38
Decreased
125,886(-2.9%)$377,6580.0%-25.37%
0
New
125,242$375,7260.0%+29.74%
33
Increased
121,434(+48.8%)$364,3020.0%-35.37%
22
New
97,299$291,8970.0%+29.74%
32
Increased
86,231(+37.0%)$258,6930.0%-41.35%
30
Unchanged
71,256$213,7680.0%-15.75%
0
Increased
62,571(+137.4%)$187,6060.0%+43.21%
25

Showing 1-20 of 53

1 / 3

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used